Skip to content

Study · Observational study · n = 5 · 2022

2 results

Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.

Wabitsch M, Fehnel S, Mallya UG, Sluga-O'Callaghan M, Richardson D, Price M, Kühnen P

Advances in therapy22 Feb 2022Cited by 24 (Europe PMC)

PMID35192151 (opens in a new tab)PMCIDPMC8862005 (opens in a new tab)DOI10.1007/s12325-022-02059-8 (opens in a new tab)PepBankPUB-35192151
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    All interviewed patients with POMC or LEPR deficiency reported reduced hunger, weight and eating, better satiety, and improved functioning after setmelanotide.

    In plain wordsAll interviewed patients reported better hunger, weight, satiety and functioning after setmelanotide than before treatment.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedReported hunger, weight and functioning
    Study

    n = 5

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Following setmelanotide treatment, all five patients reported consistent reductions in hunger and weight, decreased eating, and feeling satiated after meals in addition to substantial improvements in each area of functioning they had previously reported.
    1 context sentence
    Summary · context
    We conducted in-depth qualitative interviews in patients with POMC (n = 3) and LEPR (n = 2) deficiencies participating in an ongoing open-label extension of phase 3 clinical trials with the melanocortin receptor 4 agonist setmelanotide to describe the patient experience of hyperphagia and characteri…
  2. 02HumanObservational studyEfficacy outcome

    All interviewed patients with POMC or LEPR deficiency were very satisfied with setmelanotide's quality-of-life impact and opposed discontinuation.

    In plain wordsAll interviewed patients with POMC or LEPR deficiency were very satisfied with setmelanotide and would be upset if it stopped.

    Peptide
    Setmelanotide
    Outcome
    Not applicableTreatment satisfaction
    Study

    n = 5

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All five patients indicated they were very satisfied with the impact of setmelanotide on their quality of life and would be upset if treatment was discontinued.
    1 context sentence
    Summary · context
    We conducted in-depth qualitative interviews in patients with POMC (n = 3) and LEPR (n = 2) deficiencies participating in an ongoing open-label extension of phase 3 clinical trials with the melanocortin receptor 4 agonist setmelanotide to describe the patient experience of hyperphagia and characteri…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.